The Significance And Changes Of Levels Of VEGF And TGF-β1 In Serum In As Patients Of Active Stage After Rhtnfr:FC Therapy

Objectives:To determine the levels of vaseular endothelial growth factor (VEGF) and transforming growth factor-β1(TGF-β1) in serum of ankylosing spondylitis(AS) patients after Recombinant Human Tumor Necrosis Factor-a Receptor Ⅱ:Igg Fc Fusion Protein for injection (rhTNFR:Fc) treatment, investigate the effects of VEGF,TGF-β1 in the ankylosing spondylitisandits significance.Methods:Collected 20 cases of patients with AS of active stage that treated at the First Affiliated Hospital of Guang xi Medical University from February 2015 to December 2015.in which 20 cases followed-up for 12 weeks and 12 cases for 24 weeks.All patients recieved rhTNFR:Fc treatment and traditional medicines in first 12 weeks.In last 12 weeks,they were divided into A and B group. A group (n=8) received the same treatment,Group B(n=4) receivedonly traditional medicines. Determined the levels of VEGF and TGF-β1 levels in serumby ELISA in 0,6,12,18,24 weeks. Analysed their correlation with clinical parameters by using statistical methods.Results:1.VEGF(pg/ml):①The levels of AS patients of active stage and healthy controls were 221.71±68.57 and 40.46±11.89,respectively in 0 week.The difference was statistically significant(P<0.05).②The levels in 6,12,18(A), 18(B),24(A),24(B)weeks were 99.50±5.22,85.95±6.62,63.34±13.57,70.67±9.36, 49.56±7.05,164.40±42.65,respectively.Compared with the previous observation points, the differences were statistically significant(P<0.05).③The levels of A and B groups showed no significance difference in 18 weeks(P>0.05),but statistically significance in 24 weeks(P< 0.05).④There was a correlation between the levels of VEGF with BASDAI,BASFI,CRP,ESR,ASDAS-CRP except those of B group in 18 and 24 weeks.2.TGF-β1 (ng/ml):①The levels of AS patients of active stage and healthy controls were 10.49±3.97 and 50.06±7.70 in 0 week,respectively.The difference was statistically significant(P<0.05).②The levels in 6,12,18(A),18(B),24(A), 24(B) weeks were 20.17±3.76,28.85±9.01,34.48±3.59,36.17±7.90,47.89±6.20, 25.88±9.32,respectively.Compared with the previous observation points, the differences were statistically significant in 6,12,24(A),24(B)weeks (P< 0.05),but notstatistically significant in 18(A),18(B)weeks(P>0.05).③The levels of A and B groups showed no significant difference in 18 weeks(P>0.05),but statistically significance in 24 weeks(P<0.05).④There was no correlation between the levels of TGF-p1 in serum with BASDAI,BASFI,CRP,ESR, ASDAS-CRP at all follow-up points.Conclusion:1.The levels of VEGF inserum in AS patients of active stage were higher than those in healthy controls,but the levels of TGF-β1 in serum were lower than those of healthy controls.2.The levels of VEGF in serum in AS patients of active stage after RhTNFR:Fc treatment showed a progressive decline,and correlated with clinical parameters of BASDAI, BASFI, CRP, ESR, ASDAS-CRP.The level of VEGF would be consider as areference indexto determine disease activity and effect of RhTNFR:Fc treatment.3.RhTNFR:Fc can relieve synovitis,may promote fibrosisat the same time.